Rare loss-of-function variants in POLD1, PMS1 and FAN1 modify age at onset of motor symptoms in Huntington’s disease

Read full text
Authors: Sahar Gelfman, Rujin Wang, Adrián I. Campos, Jae-Hoon Sul, Qingqin S. Li, Silvia Álvarez, Vijay Kumar Pounjara, Chen Wang, Talaha Ali, Yuxin Zou, Anthony Marcketta, Arkopravo Ghosh
+19 more Kyoko Watanabe, Alexander Lachmann, Keyrun Adhikari, Andrey Ziyatdinov, Sean Yu, Amelia Averitt, Ashley Paynter, Michelle LeBlanc, Jones, Jonathan Marchini, Gonçalo R. Abecasis, Luca A Lotta, Aris Baras, 곽승, Jim Rosinski, Thomas F Vogt, Manuel A.R Ferreira, Eli Stahl, Giovanni Coppola
Cited by: 1
References: 26

Abstract

ABSTRACT Huntington’s disease is a rare neurodegenerative disease whose primary risk factors are inherited expansions of a CAG repeat tract in the HTT gene. Somatic expansion of these tracts leads to neuronal toxicity, neuronal death and clinical disease progression. To identify genetic factors with a major impact on disease onset and progression, we genome sequenced 18,825 individuals for the ENROLL-HD study. Our results show rare inactivating mutations in three genes, all involved in DNA damage repair, are major determinants of age of onset for motor symptoms (n=10,610) and other clinical manifestations. Heterozygote carriers of predicted loss-of-function (pLoF) variants in POLD1 and PMS1 developed motor symptoms an average 20 years (n=3; P=1×10 −5 ) and 7 years (n=6; P=2×10 −3 ) later than non-carriers, respectively. Conversely, heterozygote carriers of pLoF variants in FAN1 (n=30) developed symptoms 10 years earlier (P=2×10 −10 ). Our findings highlight therapeutic strategies and help predict age of onset for at-risk individuals.

Fields of Study & Subjects

Genetic Neurodegenerative Diseases Ubiquitin and proteasome pathways Amyotrophic Lateral Sclerosis Research

Publication details

Journal / source
medRxiv
Publisher
openRxiv
Publication date
22 June 2026
Document type
Preprint